Biomedical Engineering Reference
In-Depth Information
22. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan
PR. 2003. Influence of polymorphisms whitin thr CX3CR1 and MDR-1 genes on initial
antiretroviral therapy response. AIDS 17: 201-208.
23. Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Nakamura T, Yamada H, Kotaki
H, Sugiura W, Iwamoto A, Kitamura Y. 2004. Influence of single-nucleotide poly-
morphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and
its clinical implication for highly active antiretroviral therapy. Antivir Ther 9: 929-
935.
24. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, Weissbrich B. 2005.
No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the
virological and immunological response in treatment naive HIV-positive patients. Ann
Clin Microbiol Antimicrob 4: 3.
25. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector
SA. 2005. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and
more rapid virologic response in HIV-1 infected children. AIDS 19: 371-380.
26. Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentre F, Peytavin
G, Gerard L, Becquemont L, Aboulker JP. 2005. Absence of association between MDR1
genetic polymorphisms, indinavir pharmacokinetics and response to highly active an-
tiretroviral therapy. AIDS 19: 2127-2131.
27. Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, Bozkurt A. 2005.
Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-
hydroxytryptamine type 3 antagonists. Clin Pharmacol Ther 78: 619-626.
28. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. 2002. A common P-
glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension
in patients treated for major depression. Pharmacogenom J 2: 191-196.
29. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo
K, Sugimachi K. 2002. Neurotoxicity induced by tacrolimus after liver transplantation:
relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74:
571-572.
30. Fiegenbaum M, de Silveira FR, van der Sand CR, van der Sand LC, Ferreira ME, Pires
RC, Hutz MH. 2005. The role of common variants of ABCB1, CYP3A4 and CYP3A5
genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther
78: 551-558.
31. Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP, Lyakhovich VV. 2003. Possible
prediction of the efficiency of chemotherapy in patients with with lymphoproliferative
diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull Exp Biol Med
136: 183-185.
32. Illmer T, Schuler US, Thiede C Schwarz UI, Kim RB, Gotthard S, Freund D, Schakel
U, Ehninger G, Schaich M. 2002. MDR1 gene polymorphisms affect therapy outcome in
acute myeloid leukemia patients. Cancer Res 62: 4955-4962.
33. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bo-
dalski J, Robak T. 2004. Functional C3435T polymorphism of MDR1 gene: an impact on
genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia.
Eur J Haematol 72: 314-321.
34. Jamroziak K, Robak T. 2004. Pharmacogenomics of MDR1/ABCB1 gene: the influence
on risk and clinical outcome of haematological malignancies. Hematology 9: 91-105.
Search WWH ::
Custom Search